pmid	doi	year	title	Hugo_Symbol
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	KRAS
33509945	10.1136/jclinpath-2020-207339	2022	Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.	KRAS
33722842	10.1136/jclinpath-2020-207205	2022	Clinicopathological characteristic of ciliated muconodular papillary tumour of the lung.	KRAS
33730843	10.3324/haematol.2020.269431	2022	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.	KRAS
34015890	10.4143/crt.2021.218	2022	Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations.	KRAS
34193976	10.1038/s41375-021-01326-x	2022	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	KRAS
34472720	10.1002/cnr2.1545	2022	Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	KRAS
34799485	10.1097/PAS.0000000000001834	2022	Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.	KRAS
34998786	10.1016/j.clml.2021.12.008	2022	The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.	KRAS
35004079	10.7759/cureus.20914	2022	The Role of Tissue and Liquid Biopsy in the Clinical Management of Adult Lung Cancer Patients in King Abdul-Aziz Medical City in Riyadh, Saudi Arabia.	KRAS
35012520	10.1186/s12890-021-01803-0	2022	Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.	KRAS
35039569	10.1038/s41598-021-04736-0	2022	Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.	KRAS
35065344	10.1016/j.lungcan.2022.01.005	2022	A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer.	KRAS
35091678	10.1038/s41388-021-02162-0	2022	An mRNA expression-based signature for oncogene-induced replication-stress.	KRAS
35092381	10.31557/APJCP.2022.23.1.131	2022	Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.	KRAS
35123209	10.1016/j.esmoop.2021.100337	2022	Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.	KRAS
35133871	10.1200/JCO.21.01648	2022	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.	KRAS
35138919	10.1200/PO.21.00424	2022	Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.	KRAS
35172382	10.1002/JLB.5A0721-361R	2022	Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic.	KRAS
35198656	10.1016/j.ejro.2022.100400	2022	Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis.	KRAS
35231988	10.3760/cma.j.issn.0253-2727.2022.01.005	2022	[Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology].	KRAS
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	KRAS
35280362	10.21037/atm-22-412	2022	Genomic landscape and prognosis of patients with <i>TP53</i>-mutated non-small cell lung cancer.	KRAS
35351263	10.7499/j.issn.1008-8830.2109141	2022	Detection of <i>RAS</i> gene mutation and its clinical significance in children with acute lymphoblastic leukemia.	KRAS
35353542	10.1126/scitranslmed.abc7480	2022	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.	KRAS
35359041	10.3760/cma.j.cn112151-20211028-00781	2022	[Characteristics of fusion gene expression in acute lymphoblastic leukemia].	KRAS
35363510	10.1200/JCO.21.02840	2022	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.	KRAS
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	KRAS
35510120	10.25259/Cytojournal_18_2021	2022	Adequacy of pleural fluid cytology for comprehensive molecular analysis of lung adenocarcinoma: Experience of a large health-care system.	KRAS
35517800	10.3389/fphar.2022.875330	2022	Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.	KRAS
35582532	10.20517/cdr.2021.85	2022	Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study.	KRAS
35646685	10.3389/fonc.2022.713476	2022	A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.	KRAS
35669427	10.3389/fonc.2022.873111	2022	Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Na√Øve Metastatic Lung Adenocarcinoma.	KRAS
35723561	10.1002/cncy.22609	2022	Machine learning-based gene alteration prediction model for primary lung cancer using cytologic images.	KRAS
35727053	10.1002/cncr.34348	2022	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.	KRAS
35739536	10.1186/s12920-022-01291-z	2022	A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.	KRAS
35748237	10.2217/pme-2021-0059	2022	Targeting molecular alterations in non-small-cell lung cancer: what's next?	KRAS
35806042	10.3390/ijms23137037	2022	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.	KRAS
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	KRAS
35892000	10.5114/kitp.2022.117498	2022	Computed tomography-guided lung biopsy for molecular tests: a meta-analysis.	KRAS
35895495	10.1002/1878-0261.13295	2022	Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.	KRAS
35899444	10.3779/j.issn.1009-3419.2022.102.19	2022	[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].	KRAS
35920299	10.1096/fj.202200061RR	2022	Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context.	KRAS
35980949	10.1371/journal.pone.0273207	2022	Various impacts of driver mutations on the PD-L1 expression of NSCLC.	KRAS
35981360	10.19746/j.cnki.issn.1009-2137.2022.04.011	2022	[The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines].	KRAS
36017149	10.1155/2022/7904293	2022	Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia.	KRAS
36077521	10.3390/ijms231710117	2022	Small RNA-Seq Reveals Similar miRNA Transcriptome in Children and Young Adults with T-ALL and Indicates miR-143-3p as Novel Candidate Tumor Suppressor in This Leukemia.	KRAS
32414848	10.3324/haematol.2019.241729	2021	Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.	KRAS
32693409	10.1182/blood.2020006164	2021	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia.	KRAS
32852896	10.1002/cjp2.177	2021	Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.	KRAS
32918044	10.1038/s41375-020-01036-w	2021	An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance.	KRAS
32929178	10.1038/s41379-020-00673-x	2021	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.	KRAS
33147938	10.3324/haematol.2020.259226	2021	Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	KRAS
33277443	10.1158/1535-7163.MCT-19-0987	2021	A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.	KRAS
33393503	10.1172/JCI133090	2021	BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.	KRAS
33397922	10.1038/s41467-020-20255-4	2021	A RAC-GEF network critical for early intestinal tumourigenesis.	KRAS
33469311	10.2147/OTT.S276912	2021	Case Report: Myeloid Sarcoma Development During Treatment for B Cell Lymphoblastic Lymphoma in a Boy with KRAS/NRAS Gene Mutations.	KRAS
33475256	10.1111/1759-7714.13829	2021	Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report.	KRAS
33494549	10.3390/ph14020080	2021	Therapeutic Sequencing in ALK<sup>+</sup> NSCLC.	KRAS
33506327	10.1007/s00428-021-03032-6	2021	Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases.	KRAS
33512434	10.1182/blood.2020009082	2021	Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.	KRAS
33532178	10.1016/j.apsb.2020.07.010	2021	Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.	KRAS
33552685	10.1080/2162402X.2020.1865653	2021	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ‚â•50%: real-world data.	KRAS
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	KRAS
33572152	10.3390/cancers13040694	2021	Dual Targeting Oncoproteins MYC and HIF1Œ± Regresses Tumor Growth of Lung Cancer and Lymphoma.	KRAS
33655698	10.1002/cam4.3649	2021	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	KRAS
33656807	10.1002/cam4.3769	2021	Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.	KRAS
33671873	10.3390/cancers13040804	2021	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.	KRAS
33685866	10.1158/1078-0432.CCR-21-0032	2021	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer.	KRAS
33749383	10.1177/10935266211001308	2021	Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); <i>KMT2A/EPS15</i>, Following Blinatumomab Therapy.	KRAS
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	KRAS
33807876	10.3390/ijms22052625	2021	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.	KRAS
33847923	10.1007/s12094-021-02579-9	2021	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).	KRAS
33889526	10.21037/tlcr-20-1290	2021	High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations.	KRAS
33889527	10.21037/tlcr-21-160	2021	Concomitant mutation status of <i>ALK</i>-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib.	KRAS
33898318	10.3389/fonc.2021.647598	2021	Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.	KRAS
33902046	10.1159/000514648	2021	Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.	KRAS
34024223	10.1080/10428194.2021.1919660	2021	Co-occurrence of <i>KIT</i> and <i>NRAS</i> mutations defines an adverse prognostic core-binding factor acute myeloid leukemia.	KRAS
34035082	10.1158/0008-5472.CAN-20-2823	2021	Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma.	KRAS
34074758	10.1073/pnas.2019740118	2021	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration.	KRAS
34094825	10.1016/j.apsb.2020.10.019	2021	New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors.	KRAS
34164626	10.1158/2643-3230.BCD-20-0203	2021	Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients.	KRAS
34230493	10.1038/s41467-021-24442-9	2021	Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires Œ≤-catenin activity to drive T-cell acute lymphoblastic leukemia.	KRAS
34277785	10.21037/atm-21-2256	2021	Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces.	KRAS
34298439	10.1016/j.prp.2021.153551	2021	Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.	KRAS
34299796	10.3390/ijerph18147345	2021	The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border.	KRAS
34302028	10.1038/s41598-021-94566-x	2021	Development of thymic tumor in [LSL:Kras<sup>G12D</sup>; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis.	KRAS
34321240	10.1158/0008-5472.CAN-21-1027	2021	Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL.	KRAS
34337566	10.1016/j.xcrm.2021.100350	2021	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.	KRAS
34343999	10.1159/000514821	2021	Multigene Combined Detection by RT-qPCR Using Cytological Specimens.	KRAS
34353680	10.1016/j.lungcan.2021.06.002	2021	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.	KRAS
34412631	10.1186/s12935-021-02143-z	2021	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-Œ∫B-related signaling.	KRAS
34428672	10.1016/j.bios.2021.113568	2021	Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients.	KRAS
34434995	10.12998/wjcc.v9.i22.6287	2021	Diagnostic and prognostic value of secreted protein acidic and rich in cysteine in the diffuse large B-cell lymphoma.	KRAS
34447369	10.3389/fimmu.2021.671755	2021	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.	KRAS
34479175	10.1016/j.lungcan.2021.08.012	2021	Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.	KRAS
34548910	10.18632/oncotarget.28062	2021	Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibition.	KRAS
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	KRAS
34584457	10.2147/CMAR.S317319	2021	Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.	KRAS
34600407	10.1016/j.lungcan.2021.09.011	2021	Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.	KRAS
34638488	10.3390/cancers13195004	2021	The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.	KRAS
34703756	10.1016/j.jbo.2021.100394	2021	Estimating survival and clinical outcome in advanced non-small cell lung cancer with bone-only metastasis using molecular markers.	KRAS
34722241	10.3389/fonc.2021.692788	2021	Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.	KRAS
34749754	10.1186/s13000-021-01166-4	2021	Primary breast CD20-positive extranodal NK/T cell lymphoma with stomach involvement: a case report and literature review.	KRAS
34940123	10.3390/cimb43030149	2021	Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.	KRAS
35116717	10.21037/tcr-21-1037	2021	Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.	KRAS
35845190	10.1002/jha2.315	2021	Mutation profiles of diffuse large B-cell lymphoma transformation of splenic B-cell lymphoma/leukemia, unclassifiable on whole-exome sequencing.	KRAS
30225784	10.1007/s12253-018-0469-6	2020	The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.	KRAS
30854949	10.2174/0929867326666190222183219	2020	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.	KRAS
31439678	10.3324/haematol.2019.230375	2020	Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.	KRAS
31804006	10.1002/cam4.2757	2020	RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.	KRAS
31807922	10.1007/s00428-019-02691-w	2020	Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.	KRAS
31822503	10.1074/jbc.RA119.011443	2020	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.	KRAS
31864154	10.1016/j.thromres.2019.12.009	2020	Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.	KRAS
31989260	10.1007/s00428-020-02756-1	2020	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.	KRAS
32047266	10.1038/s41388-020-1195-6	2020	RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.	KRAS
32066856	10.1038/s41598-020-59744-3	2020	Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.	KRAS
32072746	10.1111/1759-7714.13359	2020	Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.	KRAS
32077636	10.1111/1759-7714.13361	2020	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.	KRAS
32164600	10.1186/s12885-020-6709-7	2020	Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.	KRAS
32179095	10.1016/j.mri.2020.03.002	2020	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.	KRAS
32186929	10.1080/14737140.2020.1744439	2020	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.	KRAS
32209330	10.1016/j.clml.2020.02.003	2020	RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.	KRAS
32283823	10.3390/ijms21072623	2020	Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with <i>ALK</i> Rearrangement.	KRAS
32312912	10.26508/lsa.201900601	2020	Oncogenic <i>ALK</i> <sup><i>F1174L</i></sup> drives tumorigenesis in cutaneous squamous cell carcinoma.	KRAS
32315234	10.1200/GO.20.00030	2020	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.	KRAS
32316711	10.3779/j.issn.1009-3419.2020.101.17	2020	[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].	KRAS
32327174	10.1016/j.thorsurg.2020.01.004	2020	Molecular Targets Beyond the Big 3.	KRAS
32336065	10.3779/j.issn.1009-3419.2020.101.25	2020	[Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].	KRAS
32373977	10.26355/eurrev_202004_21021	2020	Association between C-myc and K-ras gene polymorphisms and non-Hodgkin lymphoma.	KRAS
32416585	10.1016/j.resmer.2020.01.003	2020	Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study.	KRAS
32427409	10.1002/gcc.22861	2020	Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.	KRAS
32450595	10.1055/s-0039-1700994	2020	Targeted Therapy for Non-Small Cell Lung Cancer.	KRAS
32527129	10.21037/apm-19-430b	2020	Glans metastatic extra-nodal natural killer/T-cell lymphoma, nasal-type with HDAC inhibitor as maintenance therapy: a rare case report with literature review.	KRAS
32586982	10.1158/0008-5472.CAN-19-3822	2020	<i>NRAS</i> Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.	KRAS
32636302	10.1074/jbc.RA120.012915	2020	The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2.	KRAS
32747568	10.1073/pnas.2005052117	2020	Activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.	KRAS
32756609	10.1371/journal.pone.0236580	2020	Molecular profiling of non-small cell lung cancer.	KRAS
32918521	10.1002/pbc.28704	2020	Aggressive Langerhans cell histiocytosis following T-cell acute lymphoblastic leukemia.	KRAS
32944405	10.20892/j.issn.2095-3941.2020.0121	2020	Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.	KRAS
32957736	10.3390/cancers12092658	2020	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review.	KRAS
32989257	10.1038/s41388-020-01469-8	2020	Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis.	KRAS
32991719	10.1182/bloodadvances.2020002457	2020	Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.	KRAS
33053439	10.1016/j.critrevonc.2020.103119	2020	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.	KRAS
33067202		2020	Chemical Pathology of Homocysteine VIII. Effects of Tocotrienol, Geranylgeraniol, and Squalene on Thioretinaco Ozonide, Mitochondrial Permeability, and Oxidative Phosphorylation in Arteriosclerosis, Cancer, Neurodegeneration and Aging.	KRAS
33079606	10.1200/GO.20.00265	2020	Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.	KRAS
33209369	10.21037/jtd-20-1716	2020	Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma.	KRAS
33225311	10.1158/2643-3230.BCD-20-0051	2020	Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.	KRAS
33269250	10.12998/wjcc.v8.i21.5139	2020	Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma.	KRAS
35117356	10.21037/tcr-20-1675	2020	Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.	KRAS
27898263	10.1080/21541248.2016.1263718	2019	Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.	KRAS
30048416	10.1097/LBR.0000000000000534	2019	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.	KRAS
30190342	10.3324/haematol.2018.196055	2019	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.	KRAS
30355676	10.1158/1541-7786.MCR-18-0582	2019	<i>Sleeping Beauty</i> Screen Identifies <i>RREB1</i> and Other Genetic Drivers in Human B-cell Lymphoma.	KRAS
30467824	10.14670/HH-18-067	2019	Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient.	KRAS
30515612	10.1007/s10495-018-1498-z	2019	NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.	KRAS
30543838	10.1016/j.jtho.2018.12.001	2019	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.	KRAS
30548240	10.1002/cncr.31871	2019	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.	KRAS
30581133	10.1016/j.chembiol.2018.10.026	2019	Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.	KRAS
30634950	10.1186/s12885-019-5277-1	2019	Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.	KRAS
30635233	10.1016/j.clml.2018.12.009	2019	Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.	KRAS
30636374	10.1111/resp.13463	2019	Somatic mutations and immune checkpoint biomarkers.	KRAS
30662526	10.7150/jca.26947	2019	Comparison of Clinicopathological Features and Prognosis between <i>ALK</i> Rearrangements and <i>EGFR</i> Mutations in Surgically Resected Early-stage Lung Adenocarcinoma.	KRAS
30677225	10.1002/smll.201805285	2019	Developing a New qPCR-Based System for Screening Mutation.	KRAS
30741488	10.1002/dc.24154	2019	Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology.	KRAS
30741758	10.1097/COC.0000000000000508	2019	Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.	KRAS
30885850	10.1016/j.athoracsur.2019.02.010	2019	Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.	KRAS
30902917	10.1634/theoncologist.2018-0572	2019	Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.	KRAS
30953094	10.1007/s00018-019-03089-2	2019	The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.	KRAS
31016879	10.1002/cam4.2183	2019	Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.	KRAS
31025831	10.1002/cncy.22140	2019	Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.	KRAS
31028135	10.1042/BSR20190389	2019	ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.	KRAS
31037966	10.2217/fon-2018-0939	2019	Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer.	KRAS
31093306	10.1155/2019/5451290	2019	Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis.	KRAS
31141932	10.3390/cells8060514	2019	Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma.	KRAS
31186809	10.3892/ol.2019.10250	2019	High expression of microRNA-500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation.	KRAS
31199785	10.1371/journal.pgen.1008168	2019	Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.	KRAS
31277422	10.3390/genes10070505	2019	Activating Mutations in <i>PTPN11</i> and <i>KRAS</i> in Canine Histiocytic Sarcomas.	KRAS
31343834	10.1111/crj.13063	2019	Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer.	KRAS
31406302	10.1038/s41568-019-0179-8	2019	Co-occurring genomic alterations in¬†non-small-cell lung cancer biology and therapy.	KRAS
31412611	10.3390/ijms20163939	2019	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (<i>ALK</i>) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.	KRAS
31439588	10.1158/1078-0432.CCR-19-1176	2019	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer.	KRAS
31443309	10.3390/medicina55080490	2019	Malignant Pleural Effusion and Its Current Management: A Review.	KRAS
31443496	10.3390/cancers11091229	2019	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation.	KRAS
31455365	10.1186/s13000-019-0864-7	2019	ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.	KRAS
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	KRAS
31555515	10.21037/tlcr.2019.08.13	2019	Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with <i>EGFR</i> and <i>KRAS</i> mutations, and <i>ALK</i> rearrangement: a preliminary study.	KRAS
31611441	10.4103/IJPM.IJPM_69_19	2019	Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma.	KRAS
31655619	10.1186/s13287-019-1419-2	2019	Protective mechanism of artemisinin on rat bone marrow-derived mesenchymal stem cells against apoptosis induced by hydrogen peroxide via activation of c-Raf-Erk1/2-p90<sup>rsk</sup>-CREB pathway.	KRAS
31711449	10.1186/s12890-019-0964-x	2019	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.	KRAS
31910789	10.1177/0300891620902334	2019	Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma.	KRAS
35116853	10.21037/tcr.2019.06.22	2019	Lung cancer in young patients: tumour characteristics and treatment in an Irish population.	KRAS
35116907	10.21037/tcr.2019.06.23	2019	Dual drive coexistence of <i>ALK</i> rearrangement and <i>KRAS</i> mutation advanced lung adenocarcinoma and response to crizotinib.	KRAS
28280984	10.1007/s00595-017-1497-7	2018	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.	KRAS
28332047	10.1007/164_2017_16	2018	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.	KRAS
28544061	10.1111/imj.13491	2018	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma.	KRAS
28756651	10.1111/crj.12670	2018	Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.	KRAS
28757336	10.1016/j.cllc.2017.06.010	2018	Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.	KRAS
28780976	10.1016/j.cllc.2017.06.008	2018	Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.	KRAS
28843358	10.1016/j.jtho.2017.08.005	2018	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.	KRAS
28853218	10.1002/pbc.26786	2018	Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.	KRAS
28914263	10.1038/modpathol.2017.109	2018	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.	KRAS
28919190	10.1016/j.cllc.2017.08.005	2018	ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.	KRAS
29027108	10.1007/s12185-017-2340-z	2018	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.	KRAS
29186353	10.1093/annonc/mdx629	2018	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.	KRAS
29198034	10.1007/s00428-017-2268-y	2018	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.	KRAS
29361134	10.1093/annonc/mdx631	2018	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.	KRAS
29371584	10.12659/ajcr.906803	2018	Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung.	KRAS
29382756	10.1073/pnas.1716452115	2018	Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.	KRAS
29398453	10.1016/j.jmoldx.2017.11.004	2018	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.	KRAS
29439113	10.1136/gutjnl-2016-312608	2018	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.	KRAS
29486633	10.1177/1533034618754475	2018	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.	KRAS
29507487	10.3747/co.25.3867	2018	Standardizing biomarker testing for Canadian patients with advanced lung cancer.	KRAS
29516752	10.1080/13696998.2018.1450261	2018	Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.	KRAS
29535536	10.2147/OTT.S148363	2018	Response to crizotinib in a non-small-cell lung cancer patient harboring an <i>EML4-ALK</i> fusion with an atypical <i>LTBP1</i> insertion.	KRAS
29541220	10.3892/ol.2018.7859	2018	Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.	KRAS
29545318	10.1183/13993003.01467-2017	2018	Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.	KRAS
29600072	10.21037/jtd.2017.12.68	2018	Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.	KRAS
29631966	10.1016/j.cllc.2018.03.010	2018	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.	KRAS
29636358	10.1158/1078-0432.CCR-17-2452	2018	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i><sup>+</sup> and <i>ALK</i><sup>+</sup> Non-small Cell Lung Cancer.	KRAS
29652780	10.1097/BRS.0000000000002683	2018	Implication of Biomarker Mutations for Predicting Survival in Patients With Metastatic Lung Cancer to the Spine.	KRAS
29697418	10.1097/MCP.0000000000000493	2018	Recent progress in systemic treatment for lung cancer.	KRAS
29707333	10.21037/jtd.2018.01.148	2018	Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer.	KRAS
29708356	10.14735/amko2018130	2018	MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.	KRAS
29735551	10.1158/0008-5472.CAN-17-4004	2018	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	KRAS
29741520	10.4997/JRCPE.2018.104	2018	ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.	KRAS
29755699	10.18632/oncotarget.25037	2018	Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.	KRAS
29764594	10.3779/j.issn.1009-3419.2018.05.11	2018	[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].	KRAS
29764596	10.3779/j.issn.1009-3419.2018.05.13	2018	[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].	KRAS
29786757	10.1007/s12185-018-2474-7	2018	Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.	KRAS
29792386	10.1177/1010428318771472	2018	Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia.	KRAS
29807803	10.1016/j.clml.2018.05.008	2018	Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.	KRAS
29856861	10.1371/journal.pone.0198634	2018	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.	KRAS
29858031	10.1016/j.lungcan.2018.05.006	2018	Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.	KRAS
29911108	10.21037/atm.2018.05.02	2018	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.	KRAS
29947237	10.4149/BLL_2018_068	2018	Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia.	KRAS
29970498	10.21873/anticanres.12662	2018	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.	KRAS
29978950	10.1111/1759-7714.12791	2018	Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.	KRAS
29997224	10.1182/blood-2018-04-841676	2018	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.	KRAS
30005850	10.1016/j.cancergen.2018.04.119	2018	Challenges in next generation sequencing analysis of somatic mutations in transplant patients.	KRAS
30032847	10.1016/j.lungcan.2018.05.020	2018	Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.	KRAS
30037374	10.3779/j.issn.1009-3419.2018.07.06	2018	[Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant Organ Metastasis in Non-small Cell Lung Cancer].	KRAS
30050322	10.2147/CMAR.S147569	2018	Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with <i>ALK</i> rearrangement.	KRAS
30092236	10.1016/j.humpath.2018.07.029	2018	So-called non-classic ciliated muconodular papillary tumors: a comprehensive comparison of the clinicopathological and molecular features with classic ciliated muconodular papillary tumors.	KRAS
30120912	10.1002/cncr.31589	2018	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.	KRAS
30199148	10.1002/cncy.22048	2018	Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.	KRAS
30257940	10.1073/pnas.1721678115	2018	PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.	KRAS
30282799	10.1182/blood-2018-03-842088	2018	IG-<i>MYC</i> <sup>+</sup> neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.	KRAS
30322385	10.1186/s13000-018-0758-0	2018	KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma.	KRAS
30327151	10.1016/j.prp.2018.09.028	2018	Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.	KRAS
30334450	10.4149/neo_2018_171225N843	2018	PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience.	KRAS
30359792	10.1016/j.ctrv.2018.10.006	2018	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?	KRAS
30477470	10.1186/s12885-018-5078-y	2018	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.	KRAS
30504104		2018	Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.	KRAS
30546443	10.3892/ol.2018.9560	2018	ALK expression favorably impacts the prognosis of <i>NRAS</i>-mutated metastatic melanomas.	KRAS
30570921		2018	[National variation in molecular diagnostics in metastatic lung cancer].	KRAS
30680072	10.18632/oncotarget.26428	2018	Targeted therapies for advanced non-small cell lung cancer.	KRAS
30948995	10.1080/08998280.2018.1479579	2018	Early T-cell precursor acute lymphoblastic leukemia with <i>KRAS</i> and <i>DNMT3A</i> mutations and unexpected monosomy 7.	KRAS
27575422	10.1016/j.jtho.2016.08.137	2017	High Prevalence of Concomitant Oncogene Mutations¬†in Prospectively Identified Patients with¬†ROS1-Positive Metastatic Lung Cancer.	KRAS
27588400	10.18632/oncotarget.11730	2017	MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.	KRAS
27717083	10.1002/gcc.22423	2017	T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases.	KRAS
27737534	10.4143/crt.2016.365	2017	ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.	KRAS
27912827	10.1016/j.hoc.2016.08.010	2017	New Targets in Non-Small Cell Lung Cancer.	KRAS
27979926	10.3324/haematol.2016.145177	2017	CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.	KRAS
28007627	10.1016/j.jtho.2016.12.003	2017	Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).	KRAS
28024701	10.1016/j.lungcan.2016.12.001	2017	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.	KRAS
28035073	10.18632/oncotarget.14298	2017	MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.	KRAS
28078910	10.1080/10428194.2016.1260126	2017	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.	KRAS
28088512	10.1016/j.jtho.2017.01.004	2017	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.	KRAS
28103968	10.3779/j.issn.1009-3419.2017.01.02	2017	[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong].	KRAS
28122867	10.1158/2159-8290.CD-16-0330	2017	The Genetic Basis of Hepatosplenic T-cell Lymphoma.	KRAS
28132868	10.1016/j.jtho.2017.01.019	2017	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.	KRAS
28146588	10.1371/journal.pone.0171280	2017	The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.	KRAS
28157215	10.1038/bcj.2017.3	2017	Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.	KRAS
28167572	10.1634/theoncologist.2016-0194	2017	An Oncogenic <i>ALK</i> Fusion and an <i>RRAS</i> Mutation in <i>KRAS</i> Mutation-Negative Pancreatic Ductal Adenocarcinoma.	KRAS
28177518	10.1002/cncr.30539	2017	Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.	KRAS
28179026	10.1186/s40880-017-0187-6	2017	Proportion and clinical features of never-smokers with non-small cell lung cancer.	KRAS
28189832	10.1016/j.jtho.2017.02.001	2017	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.	KRAS
28212996	10.1016/j.lungcan.2016.12.005	2017	Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).	KRAS
28218040	10.1177/1010428317691413	2017	Comprehensive profiling and quantitation of oncogenic mutations in non-small cell lung carcinoma using single-molecule amplification and re-sequencing technology.	KRAS
28222308	10.1016/j.ejca.2017.01.004	2017	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.	KRAS
28235199	10.1016/j.cell.2017.02.006	2017	Multivalent Small-Molecule Pan-RAS Inhibitors.	KRAS
28237660	10.1016/j.yexmp.2017.02.014	2017	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.	KRAS
28246485	10.3748/wjg.v23.i6.1106	2017	Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.	KRAS
28259530	10.1016/j.ejso.2017.02.008	2017	Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis.	KRAS
28262675	10.1038/ncomms14581	2017	Genomic characterisation of EŒº-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.	KRAS
28280620	10.21037/jgo.2017.01.14	2017	Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.	KRAS
28285687	10.1016/j.lungcan.2017.02.008	2017	MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.	KRAS
28331826	10.21037/tlcr.2017.01.02	2017	Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.	KRAS
28350094	10.3892/ijo.2017.3935	2017	Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.	KRAS
28377205	10.1016/j.cllc.2017.03.001	2017	Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical¬†Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.	KRAS
28399384	10.1200/JOP.2016.019182	2017	Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.	KRAS
28401006		2017	Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.	KRAS
28407465	10.3904/kjim.2015.299	2017	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.	KRAS
28408464	10.1182/blood-2016-12-758979	2017	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.	KRAS
28415793	10.18632/oncotarget.16276	2017	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.	KRAS
28423587	10.18632/oncotarget.15627	2017	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.	KRAS
28424246	10.1084/jem.20160894	2017	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.	KRAS
28425994	10.1038/nature22056	2017	Modulating the therapeutic response of tumours to dietary serine and glycine starvation.	KRAS
28433077	10.1016/j.jmoldx.2016.11.004	2017	Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.	KRAS
28468034	10.3760/cma.j.issn.0529-5807.2017.05.004	2017	[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].	KRAS
28476735	10.6004/jnccn.2017.0058	2017	Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma.	KRAS
28502721	10.1016/j.jtho.2017.04.031	2017	MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.	KRAS
28507204	10.1634/theoncologist.2016-0376	2017	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.	KRAS
28507793	10.1080/2162402X.2017.1286437	2017	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.	KRAS
28510280	10.1111/ajt.14360	2017	Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse.	KRAS
28544751	10.1002/pbc.26647	2017	Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.	KRAS
28550959	10.1016/j.cllc.2017.04.006	2017	Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a¬†Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.	KRAS
28576746	10.1016/j.jtho.2017.05.018	2017	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.	KRAS
28601386	10.1016/j.cllc.2017.04.013	2017	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.	KRAS
28608966	10.1002/cncr.30794	2017	Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.	KRAS
28609002	10.1002/cncy.21866	2017	Analytic inquiry: Molecular testing in lung cancer.	KRAS
28633480	10.1093/annonc/mdx156	2017	A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.	KRAS
28687222	10.1016/j.clml.2017.06.003	2017	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.	KRAS
28754405	10.1016/j.jdermsci.2017.07.013	2017	Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides.	KRAS
28762087	10.1007/s11523-017-0520-7	2017	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).	KRAS
28838992	10.3324/haematol.2017.169870	2017	The role of constitutive activation of FMS-related tyrosine kinase-3 and <i>NRas/KRas</i> mutational status in infants with <i>KMT2A</i>-rearranged acute lymphoblastic leukemia.	KRAS
28840016	10.21037/jtd.2017.06.20	2017	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.	KRAS
28852126	10.1038/s41598-017-10366-2	2017	Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma.	KRAS
28855972	10.1186/s13148-017-0393-8	2017	Epigenetic response of imprinted domains during carcinogenesis.	KRAS
28856790	10.1111/ped.13365	2017	MSH2 deletion with CREBBP and KRAS mutations in pediatric high-hyperdiploid acute lymphoblastic leukemia.	KRAS
28866095	10.1016/j.canlet.2017.08.034	2017	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.	KRAS
28885734	10.1111/cup.13039	2017	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.	KRAS
28894396	10.2147/POR.S140579	2017	A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data.	KRAS
28932588	10.21037/jtd.2017.07.11	2017	<i>KRAS</i> mutation-positive mucinous adenocarcinoma originating in the thymus.	KRAS
29143897	10.1007/s11864-017-0513-x	2017	Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.	KRAS
29167001	10.3779/j.issn.1009-3419.2017.11.02	2017	[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].	KRAS
29167009	10.3779/j.issn.1009-3419.2017.11.10	2017	[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].	KRAS
29184034	10.1126/scisignal.aam7550	2017	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.	KRAS
29199670	10.4103/ijc.IJC_258_17	2017	Targeted therapy in nonsmall cell lung cancer.	KRAS
29296886	10.1182/bloodadvances.2017012211	2017	Constitutive Ras signaling and <i>Ink4a/Arf</i> inactivation cooperate during the development of B-ALL in mice.	KRAS
25663566	10.1007/s12016-015-8466-y	2016	Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).	KRAS
25809997	10.1111/ejh.12549	2016	Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.	KRAS
25947035	10.3109/10428194.2015.1046863	2016	Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.	KRAS
25956936	10.1007/s00330-015-3814-0	2016	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	KRAS
26254613	10.1007/s13277-015-3869-1	2016	Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.	KRAS
26381283	10.1016/j.cllc.2015.08.001	2016	EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.	KRAS
26414189	10.3109/10428194.2015.1099648	2016	Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.	KRAS
26469326	10.1097/PAI.0000000000000250	2016	CDX-2 Expression in Primary Lung Adenocarcinoma.	KRAS
26527318	10.18632/oncotarget.6259	2016	Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.	KRAS
26549032	10.1038/onc.2015.431	2016	RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines.	KRAS
26618563	10.1586/14737140.2016.1126514	2016	Emerging targeted therapies in non-small cell lung cancer.	KRAS
26620497	10.1177/1753465815617871	2016	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.	KRAS
26646246	10.1007/s00432-015-2081-4	2016	Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.	KRAS
26695526	10.1002/cncr.29812	2016	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.	KRAS
26712101	10.1016/j.cllc.2015.11.004	2016	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.	KRAS
26720421	10.1001/jamaoncol.2015.4482	2016	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.	KRAS
26777916	10.1016/S0140-6736(16)00004-0	2016	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	KRAS
26789109	10.18632/oncotarget.6671	2016	Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.	KRAS
26808549	10.1172/JCI84014	2016	Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.	KRAS
26829311	10.1016/j.jtho.2016.01.010	2016	KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.	KRAS
26848526	10.18632/oncotarget.7134	2016	Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.	KRAS
26852652	10.1016/j.bcmd.2015.11.006	2016	ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.	KRAS
26883104	10.18632/oncotarget.7356	2016	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.	KRAS
26893860	10.3892/mco.2015.690	2016	Genetic alterations in lung adenocarcinoma with a micropapillary component.	KRAS
26898615	10.1016/j.lungcan.2016.01.002	2016	K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.	KRAS
26901614	10.1016/j.ejca.2015.12.033	2016	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.	KRAS
26933125	10.1158/1078-0432.CCR-15-3000	2016	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.	KRAS
26951514	10.1007/s13277-016-4840-5	2016	Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.	KRAS
26964771	10.1016/j.jtho.2016.02.018	2016	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.	KRAS
26968843	10.1186/s12885-016-2249-6	2016	Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.	KRAS
26992209	10.18632/oncotarget.8074	2016	Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.	KRAS
27013922	10.2174/1389202916666151014221954	2016	Genetics of Bladder Malignant Tumors in Childhood.	KRAS
27033383	10.3760/cma.j.issn.0529-5807.2016.04.002	2016	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].	KRAS
27034005	10.18632/oncotarget.8427	2016	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.	KRAS
27040858	10.1016/j.lungcan.2016.03.005	2016	EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.	KRAS
27055865	10.1038/leu.2016.40	2016	Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.	KRAS
27056998	10.1093/annonc/mdw163	2016	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.	KRAS
27073482	10.3892/ol.2016.4235	2016	<i>EGFR</i>, <i>ALK</i>, <i>RET</i>, <i>KRAS</i> and <i>BRAF</i> alterations in never-smokers with non-small cell lung cancer.	KRAS
27073516	10.3892/ol.2016.4233	2016	Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.	KRAS
27080983	10.1038/modpathol.2016.66	2016	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.	KRAS
27086595	10.4132/jptm.2016.03.09	2016	Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.	KRAS
27094798	10.1016/j.jtho.2016.03.022	2016	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.	KRAS
27099101	10.1111/resp.12737	2016	Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.	KRAS
27100677	10.1371/journal.pone.0154186	2016	Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.	KRAS
27107327	10.1016/j.ejca.2016.03.012	2016	High co-expression of PD-L1 and HIF-1Œ± correlates with tumour necrosis in pulmonary pleomorphic carcinoma.	KRAS
27114375	10.1016/j.pathol.2016.02.016	2016	ALK-rearranged adenocarcinoma with extensive mucin production can mimic mucinous adenocarcinoma: clinicopathological analysis and comprehensive histological comparison with KRAS-mutated mucinous adenocarcinoma.	KRAS
27141364	10.1080/2162402X.2015.1108514	2016	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1Œ± and STAT3.	KRAS
27164089	10.3390/ijms17050683	2016	Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.	KRAS
27229929	10.1186/s12885-016-2374-2	2016	Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.	KRAS
27237031	10.1016/j.lungcan.2016.05.001	2016	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.	KRAS
27262212	10.1016/j.jtho.2016.04.033	2016	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.	KRAS
27266901	10.1016/j.rmr.2016.01.007	2016	[Molecular epidemiology of the lung cancer].	KRAS
27298405	10.1200/JCO.2016.67.2410	2016	Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.	KRAS
27379696		2016	HSP90 inhibitors in lung cancer: promise still unfulfilled.	KRAS
27402797	10.1093/jjco/hyw094	2016	Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer.	KRAS
27409166	10.18632/oncotarget.10464	2016	Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.	KRAS
27434036	10.1038/bjc.2016.208	2016	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.	KRAS
27453951	10.1172/jci.insight.86698	2016	An extra copy of <i>p53</i> suppresses development of spontaneous Kras-driven but not radiation-induced cancer.	KRAS
27460205	10.3892/or.2016.4962	2016	ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues.	KRAS
27488117	10.1007/s13277-016-5283-8	2016	IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells.	KRAS
27518729	10.1371/journal.pone.0161081	2016	Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Na√Øve Patients with Advanced Lung Adenocarcinoma.	KRAS
27544536	10.1002/cam4.809	2016	Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.	KRAS
27554588	10.1002/cam4.852	2016	Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.	KRAS
27598807	10.1016/j.ijrobp.2016.06.006	2016	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.	KRAS
27600764	10.1038/ncomms12602	2016	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.	KRAS
27615396	10.1016/j.jtho.2016.08.142	2016	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.	KRAS
27623943	10.1007/s13277-016-5357-7	2016	Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.	KRAS
27627705	10.1111/cas.13080	2016	EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.	KRAS
27655895	10.1073/pnas.1608420113	2016	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.	KRAS
27663730	10.1073/pnas.1613836113	2016	Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.	KRAS
27670423	10.1182/blood-2016-01-692855	2016	High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.	KRAS
27672108	10.1093/annonc/mdw282	2016	First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.	KRAS
27683039	10.18632/oncotarget.12238	2016	Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.	KRAS
27696251	10.1007/s12020-016-1080-9	2016	Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.	KRAS
27760592	10.3779/j.issn.1009-3419.2016.10.02	2016	[Driven Gene in Patients with Lung Squamous Cell Carcinoma: Analysis of Clinicopathologic Characteristics and Prognosis].	KRAS
27769042	10.18632/oncotarget.12705	2016	ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.	KRAS
27803402	10.2169/internalmedicine.55.6794	2016	Triple Gene Analysis Using Samples Obtained by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration.	KRAS
27835869	10.18632/oncotarget.13181	2016	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.	KRAS
27867542	10.21037/jtd.2016.09.64	2016	The expression of <i>SALL4</i> is significantly associated with <i>EGFR</i>, but not <i>KRAS</i> or <i>EML4-ALK</i> mutations in lung cancer.	KRAS
27987580	10.1016/j.lungcan.2016.10.010	2016	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.	KRAS
27997540	10.1371/journal.pmed.1002200	2016	IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.	KRAS
28101165	10.3892/etm.2016.3847	2016	Functions of microRNA-143 in the apoptosis, invasion and migration of nasopharyngeal carcinoma.	KRAS
28476195	10.1016/j.arcmed.2016.11.016	2016	Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.	KRAS
31042492	10.1016/j.jasc.2015.11.003	2016	Fine-needle aspiration of small pulmonary nodules yields material for reliable molecular analysis of adenocarcinomas.	KRAS
24897505	10.1038/leu.2014.177	2015	Evolutionary trajectories of hyperdiploid ALL in monozygotic twins.	KRAS
25053852	10.1093/neuonc/nou146	2015	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.	KRAS
25110823	10.3109/10428194.2014.953152	2015	Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication.	KRAS
25243942	10.1097/RLU.0000000000000581	2015	Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.	KRAS
25273224	10.1002/cncr.29042	2015	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.	KRAS
25344360	10.1093/annonc/mdu484	2015	Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.	KRAS
25361983	10.1093/annonc/mdu505	2015	Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.	KRAS
25371176	10.1038/leu.2014.315	2015	Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.	KRAS
25444907	10.1016/j.canlet.2014.11.024	2015	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	KRAS
25549722	10.1158/1078-0432.CCR-14-1589	2015	Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.	KRAS
25557162	10.1002/cncy.21507	2015	Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.	KRAS
25588859	10.5301/jbm.5000127	2015	Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.	KRAS
25596245	10.1309/AJCPMY8UI7WSFSYY	2015	Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas.	KRAS
25615851	10.3109/07357907.2014.1000494	2015	Mutational profiling of second primary lung cancers in patients who have received radiation for the treatment of Hodgkin's disease.	KRAS
25629635	10.1097/JTO.0000000000000487	2015	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	KRAS
25657019	10.1183/09031936.00097214	2015	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.	KRAS
25665893	10.1016/j.cllc.2014.12.009	2015	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.	KRAS
25676841	10.1159/000369860	2015	Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens.	KRAS
25682546	10.1016/j.cllc.2015.01.003	2015	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.	KRAS
25689095	10.1111/resp.12490	2015	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	KRAS
25704901	10.1016/j.rmr.2014.08.014	2015	[Targeted therapies in non-small cell lung cancer in 2014].	KRAS
25706305	10.1371/journal.pone.0117333	2015	Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.	KRAS
25711901	10.1002/cncy.21527	2015	FNA, core biopsy, or both for the diagnosis of lung carcinoma: Obtaining sufficient tissue for a specific diagnosis and molecular testing.	KRAS
25738220	10.1097/JTO.0000000000000516	2015	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	KRAS
25745045	10.1183/09031936.00097314	2015	No impact of passive smoke on the somatic profile of lung cancers in never-smokers.	KRAS
25773866	10.1016/j.lungcan.2015.02.018	2015	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.	KRAS
25776025	10.1016/j.humpath.2014.10.032	2015	An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung.	KRAS
25813151	10.1007/s13277-015-3331-4	2015	The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.	KRAS
25819217	10.1016/j.bulcan.2015.02.016	2015	[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].	KRAS
25833149	10.1159/000376552	2015	Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.	KRAS
25842168	10.1016/j.ctrv.2015.03.009	2015	Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.	KRAS
25862146	10.1016/j.lungcan.2015.03.017	2015	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.	KRAS
25910841	10.1093/neuonc/nov043	2015	Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?	KRAS
25917266	10.1038/leu.2015.107	2015	KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.	KRAS
25925381	10.1016/j.neo.2015.03.004	2015	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.	KRAS
25964588		2015	Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.	KRAS
25973127		2015	ALK-rearranged squamous cell lung cancer: a case report.	KRAS
26028064	10.7314/apjcp.2015.16.10.4147	2015	Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.	KRAS
26045026	10.1159/000430852	2015	Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data.	KRAS
26045865		2015	Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.	KRAS
26056079	10.1016/j.lungcan.2015.05.012	2015	Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.	KRAS
26095438	10.4132/jptm.2015.05.13	2015	Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma.	KRAS
26121087	10.1038/ng.3333	2015	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.	KRAS
26130140	10.3892/mmr.2015.4001	2015	A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.	KRAS
26155992	10.1002/cam4.492	2015	Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.	KRAS
26189108	10.1016/j.leukres.2015.06.005	2015	Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.	KRAS
26215190	10.1245/s10434-015-4704-z	2015	Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.	KRAS
26222068	10.1002/pbc.25683	2015	Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.	KRAS
26245900	10.1074/jbc.M115.657833	2015	The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.	KRAS
26273395	10.1111/1759-7714.12191	2015	Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements.	KRAS
26297264	10.1016/j.clml.2015.02.035	2015	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.	KRAS
26301689	10.1038/nm.3930	2015	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.	KRAS
26331813	10.1002/cncr.29531	2015	Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population.	KRAS
26332764	10.1371/journal.pone.0136659	2015	Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger.	KRAS
26339915		2015	[Molecular diagnostics of lung cancer].	KRAS
26358176	10.1038/cgt.2015.39	2015	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	KRAS
26360058	10.1371/journal.pone.0137917	2015	Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.	KRAS
26373952	10.1186/s13000-015-0409-7	2015	Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.	KRAS
26379152	10.1097/PAS.0000000000000503	2015	Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis.	KRAS
26399548	10.1038/ncomms9477	2015	Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma.	KRAS
26483338	10.3779/j.issn.1009-3419.2015.10.08	2015	[Role of HER2 in NSCLC].	KRAS
26507119	10.1080/15592294.2015.1110672	2015	Epigenetic instability at imprinting control regions in a Kras(G12D)-induced T-cell neoplasm.	KRAS
26517679	10.18632/oncotarget.5434	2015	Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.	KRAS
26536196	10.1097/JTO.0000000000000665	2015	Clinical Implications of Variant ALK FISH Rearrangement Patterns.	KRAS
26555338	10.1371/journal.pone.0142306	2015	Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.	KRAS
26581482	10.1186/s13104-015-1675-x	2015	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.	KRAS
26627242	10.1073/pnas.1520329112	2015	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.	KRAS
26677401	10.1186/s13148-015-0162-5	2015	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.	KRAS
26995877		2015	[Companion Diagnostics for Solid Tumors].	KRAS
23988776	10.1183/09031936.00018013	2014	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.	KRAS
24067137	10.3109/10428194.2013.847934	2014	Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.	KRAS
24139827	10.1016/j.cllc.2013.08.002	2014	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.	KRAS
24397598	10.3109/10428194.2013.878461	2014	Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma.	KRAS
24505083	10.1182/blood-2013-01-477620	2014	Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.	KRAS
24610751	10.1002/pbc.24797	2014	Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS.	KRAS
24691006	10.1371/journal.pone.0092147	2014	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.	KRAS
24729716	10.2147/OTT.S60122	2014	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.	KRAS
24799949	10.4103/1742-6413.129183	2014	Utility of molecular tests in cytopathology.	KRAS
24809777	10.1038/bjc.2014.218	2014	Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.	KRAS
24828667	10.1097/JTO.0000000000000142	2014	Small-cell lung cancers in patients who never smoked cigarettes.	KRAS
24857124	10.14694/EdBook_AM.2014.34.e353	2014	Management and future directions in non-small cell lung cancer with known activating mutations.	KRAS
24885803	10.5858/arpa.2013-0388-OA	2014	ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.	KRAS
24885982	10.1148/radiol.14140789	2014	ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.	KRAS
24888607	10.1002/jso.23646	2014	Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.	KRAS
24903964	10.1007/s00432-014-1715-2	2014	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.	KRAS
24913807	10.1007/s12032-014-0034-4	2014	Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.	KRAS
24925809	10.1016/j.cllc.2014.04.004	2014	Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.	KRAS
24982390		2014	Rare co-existence of mutation in KRAS and ALK gene re-arrangement in an adenocarcinoma patient--a case report.	KRAS
25010763		2014	[Criteria of the molecular pathology testing of lung cancer].	KRAS
25043004	10.1038/nature13495	2014	Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.	KRAS
25105841	10.1038/ncomms5654	2014	Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.	KRAS
25131476		2014	[Anaplastic lymphoma kinase fusion gene expression, clinical pathological characteristics and prognosis in 95 Chinese patients with non-small cell lung cancer].	KRAS
25189939	10.3892/mmr.2014.2533	2014	Learning curve for endobronchial ultrasound‚Äëguided transbronchial needle aspiration: experience of a community‚Äëbased teaching hospital.	KRAS
25193384	10.1158/0008-5472.CAN-14-0268	2014	ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.	KRAS
25204082		2014	NRAS mutations in de novo acute leukemia: prevalence and clinical significance.	KRAS
25217578	10.1093/jnci/dju256	2014	Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.	KRAS
25253770	10.1182/blood-2014-04-531871	2014	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	KRAS
25275049		2014	Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment.	KRAS
25288236	10.1016/j.humpath.2014.08.005	2014	Molecular alterations in non-small cell lung carcinomas of the young.	KRAS
25342991	10.1177/1758834014532510	2014	Novel agents in development for advanced non-small cell lung cancer.	KRAS
25364578	10.7497/j.issn.2095-3941.2014.03.003	2014	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.	KRAS
25425670	10.1073/pnas.1420822111	2014	Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics.	KRAS
25563851	10.2174/187446720701150105171219	2014	Molecular testing and personalized treatment of lung cancer.	KRAS
26767032	10.1111/1759-7714.12111	2014	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.	KRAS
23392229	10.1097/JTO.0b013e318283558e	2013	Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.	KRAS
23403319	10.3324/haematol.2012.067983	2013	Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.	KRAS
23495083	10.1002/cncy.21288	2013	Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.	KRAS
23729361	10.1158/1078-0432.CCR-13-0318	2013	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	KRAS
23841470	10.1164/rccm.201305-0843PP	2013	The impact of genomic changes on treatment of lung cancer.	KRAS
23919423	10.3109/01902148.2013.819535	2013	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.	KRAS
23932486	10.1016/j.lungcan.2013.07.013	2013	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.	KRAS
24166518	10.1200/JCO.2012.48.5292	2013	Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.	KRAS
24192124	10.2217/pgs.13.177	2013	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.	KRAS
24200637	10.1016/j.cancergen.2013.09.004	2013	Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.	KRAS
21720997	10.1002/cncr.26311	2012	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	KRAS
22080568	10.1158/0008-5472.CAN-11-1403	2012	Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.	KRAS
22135231	10.1158/1535-7163.MCT-11-0692	2012	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	KRAS
22317764	10.1158/1078-0432.CCR-11-2511	2012	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	KRAS
21209378	10.1182/blood-2010-09-305128	2011	High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.	KRAS
21311557	10.1038/leu.2011.15	2011	Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model.	KRAS
21586752	10.1182/blood-2010-12-326058	2011	Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.	KRAS
20183914	10.1245/s10434-009-0808-7	2010	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	KRAS
20237506	10.1038/leu.2010.39	2010	Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.	KRAS
20624322	10.1186/1476-4598-9-188	2010	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	KRAS
20688547	10.1016/j.bcmd.2010.07.007	2010	Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.	KRAS
19164213	10.1200/JCO.2008.18.0463	2009	Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.	KRAS
19234440	10.1038/modpathol.2009.2	2009	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	KRAS
19551857	10.1002/ijc.24681	2009	The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.	KRAS
19667264	10.1200/JCO.2009.22.6993	2009	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	KRAS
17910045	10.1002/gcc.20502	2008	Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.	KRAS
18663146	10.1182/blood-2008-03-147587	2008	K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.	KRAS
18701506	10.1158/0008-5472.CAN-08-0101	2008	Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.	KRAS
18006851	10.1158/0008-5472.CAN-07-0986	2007	16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway.	KRAS
16533526	10.1016/j.leukres.2006.02.004	2006	PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.	KRAS
16923573	10.1080/10428190600565925	2006	Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations.	KRAS
16969076	10.4161/cbt.5.8.3251	2006	Recurrent KRAS codon 146 mutations in human colorectal cancer.	KRAS
12824925	10.1111/j.1349-7006.2003.tb01436.x	2003	Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China.	KRAS
3057505	10.1073/pnas.85.23.9268	1988	Analysis of RAS oncogene mutations in human lymphoid malignancies.	KRAS
